TNF-SAM2

TNF-SAM2 is a recombinant mutant (mutein) of human tumor necrosis factor-alpha (TNF-α) developed by Asahi Kasei. It was engineered to improve the therapeutic index of native TNF-α by modifying the N-terminal amino acid sequence, aiming to maintain potent anti-tumor activity while minimizing systemic side effects. The drug has been primarily investigated in Japan for the treatment of malignant gliomas, such as glioblastoma multiforme and anaplastic astrocytoma. It is typically administered locally via an Ommaya reservoir into the post-operative tumor cavity or systemically through intravenous infusion. Its mechanism of action involves binding to TNF receptors, which triggers apoptotic cell death in tumor cells and modulates the tumor microenvironment through inflammatory signaling and induction of hemorrhagic necrosis.

Other names

tumor necrosis factor-alpha SAM2TNF-alpha SAM2SAM2SAM-2SAM 2mutant tumor necrosis factor-alpha